A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a sequential, randomized, double-blind, placebo controlled, multiple dose, dose
escalation study in subjects with OA knee pain (n=32; 8/cohort). In each cohort, subjects
will be randomized 3:1 to receive SC AMG 403 or placebo once every 4 weeks for a total of 4
doses (Q28D x 4).